Back to search results

Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

This study is testing a single dose of JADE101, given as an injection under the skin, in healthy Japanese and Chinese volunteers. The main goals are to see how safe JADE101 is and if people can tolerate it well. Researchers will also look at how the body processes JADE101. You may be able to join if you are a healthy Japanese or Chinese person between 18 and 55 years old, born in Japan or China, and meet specific weight and BMI requirements. The study aims to enroll 40 participants, but its current recruitment status is unclear.

Study design
This is a Phase 1 interventional study. It will involve a single dose of JADE101 and plans to enroll 40 healthy participants.
What's involved
You would need to comply with study site stays, scheduled visits, and study procedures. The study will monitor you from Day 1 through 48 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and tolerability from Day 1 through 48 weeks after receiving JADE101.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07525947

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

Recruiting
PHASE1Ages 18–55InterventionalBasic science
Jade Biosciences, Inc.
~40 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:JADE101

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participants
Measured over Day 1 through 48 weeks
+4 more outcomes measured

Conditions

Healthy Volunteers (HV)

Explore related trials

Healthy Volunteers

NCT07525947

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Parexel Early Phase Clinical Unit (EPCU)

    Glendale, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Li Li, MD · STUDY_DIRECTOR · Jade Biosciences

Who to contact

Han
[email protected]
+1-888-228-7425
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participantsDay 1 through 48 weeks

    Incidence of treatment-emergent adverse events

  • CmaxDay 1 through 48 weeks

    Maximum observed serum concentration

  • TmaxDay 1 through 48 weeks

    Time to reach Cmax

  • AUClastDay 1 through 48 weeks

    The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration

  • T1/2Day 1 through 48 weeks

    Apparent first-order terminal elimination half-life